(The Feb. 20 story was corrected to remove a reference to Albertsons dropping IPO plans in 2017 in paragraph 4)
(Reuters) - U.S. grocer Albertsons Cos Inc said it would buy drug store chain Rite Aid Corp RAD.N to create a company with $83 billion in annual revenue, giving it more clout to compete with bigger chains in an industry fearing the entry of Amazon.Com AMZN.O.
The deal is the latest in a wave of consolidation in the drug retailing sector, which is looking to cut costs amid weak reimbursement rates and lower generic drug prices. At the same time, Amazon’s foray is widely expected to disrupt the industry, prompting drug chains to beef up their businesses.
Backed by private equity firm Cerberus Capital Management, Albertsons hopes the deal will help it become a formidable competitor to CVS Corp CVS.N and Walgreens WBA.O, and give its private equity owners a way to exit their decade-long investment in the grocer.
Cerberus first took a stake in Albertsons in 2006 and scaled it through acquisitions including that of Safeway in 2014. It planned to sell its stake through an IPO.
“The new company will have an expanded footprint and be ranked first or second in 66 percent of the top metropolitan areas in the United States and will be ranked first or second in 70 percent of pharmacy locations,” Albertsons and Rite Aid said in a joint statement on Tuesday.
Albertsons owns about 2,300 supermarket stores mainly on the east and west coasts of the United States and also operates about 1,800 pharmacies. Rite Aid owns about 2,569 drug stores, after it sold 1,932 pharmacies to Walgreens for $4.38 billion.
Albertsons said it would convert its existing pharmacies to Rite Aid stores and let existing Rite Aid outlets operate as stand alone pharmacies.
Together, the combined company will operate about 4,350 pharmacy counters and 320 clinics across 38 states and Washington.
Within three years the combined company is expected to deliver annual run-rate cost savings of $375 million, with more than 60 percent within the first two years, the companies said.
The combined company is expected to generate pre-tax earnings of about $3.7 billion within three years, they said.
Rite Aid’s shares, which initially surged by as much as 25 percent premarket on Tuesday, were trading up 2.3 percent at $2.18 in afternoon trading.
The deal follows Amazon.com Inc's AMZN.O move to team up with Berkshire Hathaway Inc BRKa.N and JPMorgan Chase & Co JPM.N to form a not-for-profit company to provide health care for their employees, challenging the existing U.S. healthcare system.
The threat of Amazon making further inroads has jolted U.S. drug store chains into action after several years of declines in traffic and sales at front-end stores.
Larger rival CVS Health Corp CVS.N reached a $69 billion deal to buy insurer Aetna Inc AET.N last month, while Walgreens is also reported to have made a takeover approach for drug distributor AmerisourceBergen Corp ABC.N.
“Drug retailing has had its own challenges with reimbursement pressure and weak front-end sales as evidenced in Rite-Aid’s weak profits over the last couple of years,” said Mickey Chadha, a vice president with credit ratings agency Moody’s.
“Competing with much larger and more diversified drug retailers like CVS and Walgreens will be a formidable challenge,” he said.
Based on the enterprise value of both Albertsons and Rite Aid, the combined company is valued at $24 billion, an Albertsons Companies’ spokeswoman told Reuters.
Rite Aid shareholders can elect to get either one Albertsons common share plus about $1.83 in cash, or 1.079 Albertsons common shares for every 10 shares they hold.
Shareholders of Rite Aid, which had a market cap of $2.33 billion at midday Tuesday, will own between 28 percent and 29.6 percent of the combined company, while Albertsons’ shareholders will own the rest based on the elections, the companies said.
Depending on whether Rite Aid shareholders choose to be paid in cash and Albertsons stock or only stock, the deal values Rite Aid at between $1.30 and $2.65 per share, Evercore ISI analyst Ross Muken said.
Additional reporting by Shalini Nagarajan and Vibhuti Sharma in Bengaluru; Editing by Anil D’Silva and Savio D’Souza
Our Standards: The Thomson Reuters Trust Principles.